NRAS Gene Expression and Its Clinical Significance in Patients with Acute Myeloid Leukemia.
10.7534/j.issn.1009-2137.2020.01.013
- Author:
Tian-Tian LI
1
;
Jun LI
1
;
Ying-Hua GENG
1
;
Feng ZHANG
1
;
Lin LIU
1
;
Yan-Li YANG
2
,
3
Author Information
1. Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province, China.
2. Department of Hematology, The First Affiliated Hospital of Bengbu Medical College, Bengbu 233000, Anhui Province, China,E-mail:yangyanli0702@
3. com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):76-81
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the mutation rate and distribution of Homo sapiens neuroblastoma RAS viral oncogene homolog (NRAS) gene in the patients with acute myeloid leukemia.
METHODS:The genomic DNA of bone marrow was screened by polymerase chain reaction (PCR) and sequencing for NRAS mutations. At the same time, the mutations of ASXL1, DNMT3A, TET2, CEBPA, FLT3, IDH2, NPM1 and c-KIT genes were also detected to analyze the relation with NRAS mutations.
RESULTS:A total of 11 NRAS mutations were found in 108 patients with initial acute myeloid leukemia and the mutation rate was 10.2%, including 6 cases of G12D, 3 cases of G13D, and 2 cases of G61K. In the mutation group, the peripheral blood leukocyte count was higher (P＜0.05), more likely to occur in the M subtype, and the M subtype was mutually exclusive (P＜0.05). Moreover, the mutant group was more likely to express CD13 than the non-mutation group (P＜0.05), while no statistic difference was found in age, gender, hemoglobin level, platelet count, lactate dehydrogenase level, bone marrow blast, cytogenetics, complete remission rate and overall survival (P＞0.05).
CONCLUSIONS:The mutation of NRAS gene has no effect on the prognosis of AML patients.
